Activation of S1P2 is protective against cisplatin‐induced peripheral neuropathy.

Platinum-based chemotherapy drugs commonly used for cancer treatment can cause peripheral neuropathy, which damages nerves in the peripheral nervous system and affects patients' quality of life. A recent study found that activating the S1P2 receptor can counteract the effects of cisplatin-induced peripheral neuropathy, suggesting that targeting this receptor could be a potential treatment approach. The study used animal models and gene sequencing analysis to investigate the neuroprotective effects of S1P2 activation and found that it restored gene dysregulation associated with nerve growth and mitochondrial functions. These findings indicate that S1P2 activation may be a promising therapeutic target for cisplatin-induced peripheral neuropathy. [Extracted from the article]